Organogenesis’ PuraPly AM Shows Strong Success in Diabetic Foot Ulcer Trial
Organogenesis Holdings says PuraPly AM helps diabetic foot ulcers heal faster than standard care alone in a clinical trial.
/ 1659 items
#XY↓
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.
ImmunityBio Quickly Fixes FDA Ad Concerns: Podcast Pulled, TV Spot Never Aired
ImmunityBio addressed FDA ad concerns, removed a podcast, and clarified ANKTIVA info while tightening rules on future promotions.
Tyra Biosciences Receives Buy Rating – Key 2026 Data Ahead
Tyra Biosciences’ dabogratinib shows promise: works well for bladder cancer & dwarfism with fewer side effects. Big 2026 trials ahead.
Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.